Expert Interview
A Second Look: Evaluating the topline results of the Phase 3 TRuE-AD3 clinical trial of Opzelura (Ruxolitinib Cream) in children with atopic dermatitis.
Ticker(s): INCYInstitution: MassGeneral Brigham
- Instructor in Dermatology and clinician researcher with experience leading both basic and clinical research projects and aim to work at their interface, developing clinical and translational projects to facilitate mechanism-based treatment of dermatologic disease and improve pediatric patient care.
- Background in infectious disease and host-pathogen interactions t
- Manages 15 patients with DEB
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
